| Title |
Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency
|
|---|---|
| Published in |
Clinical Drug Investigation, July 2013
|
| DOI | 10.1007/s40261-013-0110-0 |
| Pubmed ID | |
| Authors |
Kenneth C. Lasseter, Ander Sologuren, Anna La Noce, Stacy C. Dilzer |
| Abstract |
Bilastine is a novel second-generation H1 antihistamine, which has not shown sedative or cardiotoxic effects in clinical trials and in post-marketing experience so far, developed for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria. It has recently been granted marketing authorization for these therapeutic indications in adults and adolescents at a once-daily oral dose of 20 mg in several European countries. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Argentina | 1 | 33% |
| United Kingdom | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 39 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 10% |
| Researcher | 4 | 10% |
| Student > Bachelor | 4 | 10% |
| Other | 3 | 8% |
| Student > Doctoral Student | 2 | 5% |
| Other | 5 | 13% |
| Unknown | 17 | 44% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 13% |
| Medicine and Dentistry | 4 | 10% |
| Biochemistry, Genetics and Molecular Biology | 3 | 8% |
| Agricultural and Biological Sciences | 2 | 5% |
| Arts and Humanities | 1 | 3% |
| Other | 7 | 18% |
| Unknown | 17 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 April 2014.
All research outputs
#13,039,026
of 22,715,151 outputs
Outputs from Clinical Drug Investigation
#620
of 959 outputs
Outputs of similar age
#100,782
of 197,220 outputs
Outputs of similar age from Clinical Drug Investigation
#10
of 21 outputs
Altmetric has tracked 22,715,151 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 959 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one is in the 34th percentile – i.e., 34% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,220 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.